Japan Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others), And By City - Forecasts From 2025 To 2030

Japan Pain Management Drugs Market Size:

Japan pain management drugs market is anticipated to grow at a CAGR of 2.98% from 2025 to 2030.

The market growth is majorly attributed to the rising geriatric population in Japan, and low fertility rates, coupled with improving life expectancy on account of improving nutrition, low prevalence of diseases, and availability of state-of-the-art medical and pharmacological technologies in the country is increasing the number of older age people.

According to the “Statistical Handbook of Japan 2024”, issued by the Ministry of Internal Affairs and Communication, by 2050, the population aged 65 years and above will account for 38.7% of total communication. Likewise, as per the “Annual Report on Annual Society FY2024”, as of October 2023, the population aged 74 years and above was 20.08 million and accounted for 16.1% of the total population.

Besides the growing old-age population the chronic disease prevalence in Japan has also shown constant growth over the years which is also anticipated to drive the demand for pain management drugs as they assist in refracting pain. According to the Global Cancer Observatory, in 2022, nearly 1,005,157 new cancer cases were reported in Japan and the number of deaths reached 426,278. Hence, the same source also stated that prostate, lung, and stomach-related cancer cases were most commonly reported.

Moreover, the favorable policies and schemes by the Japanese government to increase healthcare access to rural societies followed by progression in over-the-counter drug sales have provided new growth prospects for the pain management drugs market in Japan. Likewise, various key market players namely Shionogi Inc. and Daiichi Sankyo have well-established customer bases in Japan and the companies are forming strategic collaborations with global firms such as Pfizer Inc. to improve their product offering which is estimated to stimulate the market growth.

Japan Pain Management Drug Market Segmentation

• By Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Opioid
    • Strong Opioid
    • Weak Opioid
  • Antidepressants
  • Anticonvulsant Drugs
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Indication
  • Cancer
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Others
• By City
  • Tokyo
  • Yokohama
  • Osaka
  • Nagoya
  • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. JAPAN PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. JAPAN PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. JAPAN PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. JAPAN PAIN MANAGEMENT DRUGS MARKET BY CITY

8.1. Introduction

8.2. Tokyo

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Yokohama

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. Osaka

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. Nagoya

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

8.6. Others

8.6.1. By Drug Type

8.6.2. By Distribution Channel

8.6.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Novartis Pharmaceuticals Corporation (Novartis AG)

10.2. Eli Lilly and Company

10.3. Pfizer Inc.

10.4. GlaxoSmithKline plc

10.5. Sanofi S.A

10.6. Johnson & Johnson

10.7. Viatris Inc.

10.8. DAIICHI SANKYO COMPANY, LIMITED

10.9. Shionogi Inc.

10.10. Asahi Kasei Pharma Corporation.

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

Novartis Pharmaceuticals Corporation (Novartis AG)

Eli Lilly and Company

Pfizer Inc.

GlaxoSmithKline plc

Sanofi S.A

Johnson & Johnson

Viatris Inc.

DAIICHI SANKYO COMPANY, LIMITED

Shionogi Inc.

Asahi Kasei Pharma Corporation